Search | Clinical Trials Finder

Conditions: Kidney Cancer
Interventions: Biological/Vaccine: therapeutic autologous dendritic cells.; Biological
Lead sponsor: Lisata Therapeutics, Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: HIV, Cardiovascular Risk Factor
Interventions: ABCS training; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 40 Years to 79 Years
Enrollment: 4,277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Rochester, New York

Conditions: HIV Infections
Interventions: In Vitro Diagnostic Device; Device
Lead sponsor: Chembio Diagnostic Systems, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 2,808 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: La Jolla, California • Fort Lauderdale, Florida • Baltimore, Maryland + 2 more

Conditions: Diabetes Mellitus, Type 1
Interventions: ACCU-CHEK; Device
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 11
States / cities: Montgomery, Alabama • Huntington Beach, California • Atlanta, Georgia + 8 more

Conditions: Non-Small Cell Lung Cancer, Epigenetic Therapy
Interventions: Azacitidine, Entinostat, Nivolumab, CC-486 300; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 5
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Baltimore, Maryland + 1 more

Conditions: Long COVID, Insulin Resistance, Insulin Sensitivity
Interventions: Adipose Tissue Biopsy, Steady State Plasma Glucose (SSPG) Test; Procedure · Diagnostic Test
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Palo Alto, California

Conditions: Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease (NAFLD)
Interventions: Velacur, MRI, Blood sample collection for biomarkers, Liver biopsy; Diagnostic Test
Lead sponsor: Emory University; Other
Eligibility: 2 Years to 20 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Lung Cancer
Interventions: cetuximab, radiation therapy; Biological · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 175
States / cities: Scottsdale, Arizona • Hollywood, Florida • Jacksonville, Florida + 107 more

Conditions: Health Promotion, Wellness Program
Interventions: Email, Loss frame, Testimonial (medical expert), Testimonial (rank-and-file), Social norms (percentage), Social norms (number); Behavioral
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years and older
Enrollment: 13,546 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Multiple Myeloma
Interventions: Bortezomib 1 mg/m2, Bortezomib 1.3 mg/m2, Bortezomib 1.6 mg/m2, Melphalan; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years to 76 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Alzheimer´s Disease
Interventions: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg, Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg, Placebo solution: Human Albumin 0.25% - 4 mL/kg, Placebo solution: Human Albumin 0.25% - 2 mL/kg; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 34 more

Conditions: Hypertension
Interventions: Valsartan 0.25 mg/kg, Valsartan 1.0 mg/kg, Valsartan 4.0 mg/kg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Months to 5 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: USA, New Jersey

Conditions: Colorectal Cancer
Interventions: Fecal immunochemical test; Other
Lead sponsor: University of Chicago; Other
Eligibility: 20 Years to 80 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Chicago, Illinois • Ann Arbor, Michigan • New York, New York

Conditions: Kidney Transplant Rejection
Interventions: Donor-derived cell-free DNA (AlloSure®), Standard care, Peripheral blood gene expression profiling (AlloMap Kidney), Analytic platform (IBox); Diagnostic Test · Other
Lead sponsor: CareDx; Industry
Eligibility: 18 Years and older
Enrollment: 4,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 72
States / cities: Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 54 more

Conditions: Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions: Biopsy of Prostate, Biospecimen Collection, Magnetic Resonance Imaging, Patient Observation, Questionnaire Administration, Therapeutic Testosterone; Procedure · Other · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Breast Cancer
Interventions: trastuzumab, cyclophosphamide, doxorubicin hydrochloride, lapatinib ditosylate, paclitaxel, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Hypertension, Pregnancy-Induced, Pre-eclampsia
Interventions: Ibuprofen, Acetaminophen; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Cancer, Hematologic Disorder, Rheumatologic Disorder, Infertility
Interventions: Ovarian Cryopreservation; Procedure
Lead sponsor: Vlad Radulescu; Other
Eligibility: 12 Years to 41 Years · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 2
States / cities: Lexington, Kentucky • Louisville, Kentucky

Conditions: Chronic Wrist Pain, Chronic Elbow Pain
Interventions: Not listed
Lead sponsor: Southern California Institute for Research and Education; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Diabetes Mellitus, Type 2
Interventions: Remote Patient Monitoring; Device
Lead sponsor: Tracy Jalbuena MD; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Rockport, Maine

Conditions: Non-Hodgkin's Lymphoma
Interventions: CHOP, Alemtuzumab, Plasma Samples; Drug · Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes
Interventions: busulfan, cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation; Drug · Procedure
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Peanut Allergy, Multi-food Allergy
Interventions: Omalizumab, Placebo for Omalizumab, Multi-Allergen Oral Immunotherapy, Placebo for Multi-Allergen Oral Immunotherapy, Double-Blind Placebo-Controlled Food Challenge Based Treatment; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Year to 55 Years
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 10
States / cities: Little Rock, Arkansas • Stanford, California • Denver, Colorado + 7 more

Conditions: Knee Replacement
Interventions: Aquamantys, Tourniquet; Device
Lead sponsor: Stephen Duncan; Other
Eligibility: 18 Years to 100 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Lexington, Kentucky

Search by objective public record fields.

Vaccine Therapy in Treating Patients With Kidney Cancer

Translating the ABCS Into HIV Care

Evaluation of the Performance of Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 Rapid Test

ACCU-CHEK Connect Personal Diabetes Management Study (PDM CONNECT)

Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

Non-Invasive Diagnostic Tests for MASLD in Pediatric Population

Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Assessing the Impact of myHealth Rewards Program-related Communications on Enrollment: Replication

Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma

A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease

Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure

FITting Non-invasive Tests in Lynch Syndrome Surveillance

Evaluation of Patient Outcomes From the Kidney Allograft Outcomes AlloSure Registry

Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

The Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy

Ovarian Tissue Freezing For Fertility Preservation In Women Facing A Fertility Threatening Medical Diagnosis/Treatment

Effect of Celliant Materials on Pain and Blood Oxygenation in Subjects With Chronic Elbow and Wrist Pain

Effect of Remote Patient Monitoring and Patient Education on Patient Activation and Glycemic Control in Individuals With Type 2 Diabetes

CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas

Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

Total Knee Replacement With Tourniquet or Aquamantys